Skip to main content
. 2006 Apr 19;2006(2):CD005321. doi: 10.1002/14651858.CD005321.pub2

36. Clinical benefit table: Hylan G‐F20 versus hyaluronan.Continuous outcome measure.

Study TIme Treatment Outcome (scale) N of Pts Baseline Mean End of Study Mean Absolute Benefit Relative Difference
Wobig 1999 1‐4 wk E: Hylan G‐F 20 Weight bearing pain (0‐100 mm VAS) 38 70 40 ‐1 (I) ‐1.4% (I)
    C: Artz   35 72 43    
Wobig 1999 1‐4 wk E: Hylan G‐F 20 Pain at night (0‐100 mm VAS) 38 26 12 1 (W) 3.3% (W)
    C: Artz   35 30 15    
Wobig 1999 5‐13 wk E: Hylan G‐F 20 Weight bearing pain (0‐100 mm VAS) 38 70 32 ‐14 (I) ‐19.4% (I)
    C: Artz   35 72 48    
Wobig 1999 5‐13 wk E: Hylan G‐F 20 Pain at night (0‐100 mm VAS) 38 26 13 0 0%
    C: Artz   35 30 17    
Wobig 1999 1‐4 wk E: Hylan G‐F 20 Weight bearing pain (0‐100 mm VAS) 38 70 40 ‐7 (I) ‐9.9% (I)
    C: Healon   39 71 48    
Wobig 1999 1‐4 wk E: Hylan G‐F 20 Pain at night (0‐100 mm VAS) 38 26 12 ‐1 (I) ‐2.9% (I)
    C: Healon   39 35 22    
Wobig 1999 5‐13 wk E: Hylan G‐F 20 Weight bearing pain (0‐100 mm VAS) 38 70 32 ‐5 (I) ‐7.0% (I)
    C: Healon   39 71 38    
Wobig 1999 5‐13 wk E: Hylan G‐F 20 Pain at night (0‐100 mm VAS) 38 26 13 6 (W) 17.1% (W)
    C: Healon   39 35 16    
Atamaz 2005 1‐4 wk E: Hylan G‐F 20 WOMAC pain (Likert) 20 12.4 8.3 0 0
    C: Orthovisc   20 13.4 9.3    
Atamaz 2005 5‐13 wk E: Hylan G‐F 20 WOMAC pain (Likert) 20 12.4 8.7 ‐1.5 (I) ‐11.2% (I)
    C: Orthovisc   20 13.4 11.2    
Atamaz 2005 14‐26 wk E: Hylan G‐F 20 WOMAC pain (Likert) 20 12.4 10.4 ‐0.5 (I) ‐3.7% (I)
    C: Orthovisc   20 13.4 11.9    
Atamaz 2005 36 wk E: Hylan G‐F 20 WOMAC pain (Likert) 20 12.4 10.4 1.0 (W) 7.5% (W)
    C: Orthovisc   20 13.4 10.4    
Atamaz 2005 45‐52 wk E: Hylan G‐F 20 WOMAC pain (Likert) 20 12.4 10.2 0 0
    C: Orthovisc   20 13.4 11.2    
Atamaz 2005 1‐4 wk E: Hylan G‐F 20 Spontaneous pain (0‐100 mm VAS) 20 85.0 64.0 6.4 (W) 9.1% (W)
    C: Orthovisc   20 70.3 42.9    
Atamaz 2005 5‐13 wk E: Hylan G‐F 20 Spontaneous pain (0‐100 mm VAS) 20 85.0 50.7 ‐22.4 (I) ‐31.9% (I)
    C: Orthovisc   20 70.3 58.4    
Atamaz 2005 14‐26 wk E: Hylan G‐F 20 Spontaneous pain (0‐100 mm VAS) 20 85.0 51.7 ‐29.2 (I) ‐41.5% (I)
    C: Orthovisc   20 70.3 66.2    
Atamaz 2005 36 wk E: Hylan G‐F 20 Spontaneous pain (0‐100 mm VAS) 20 85.0 51.7 ‐15.2 (I) ‐21.6% (I)
    C: Orthovisc   20 70.3 52.2    
Atamaz 2005 45‐52 wk E: Hylan G‐F 20 Spontaneous pain (0‐100 mm VAS) 20 85.0 49.0 ‐22.4 (I) ‐31.9% (I)
    C: Orthovisc   20 70.3 56.7    
Atamaz 2005 1‐4 wk E: Hylan G‐F 20 SF‐36 pain 20 25.6 59.4 22.7 (I) 62.4% (I)
    C: Orthovisc   20 36.4 47.5    
Atamaz 2005 5‐13 wk E: Hylan G‐F 20 SF‐36 pain 20 25.6 58.8 41.6 (I) 114.3% (I)
    C: Orthovisc   20 36.4 28.0    
Atamaz 2005 14‐26 wk E: Hylan G‐F 20 SF‐36 pain 20 25.6 55.7 30.6 (I) 84.1% (I)
    C: Orthovisc   20 36.4 35.9    
Atamaz 2005 36 wk E: Hylan G‐F 20 SF‐36 pain 20 25.6 43.8 9.3 (I) 25.5% (I)
    C: Orthovisc   20 36.4 45.3    
Atamaz 2005 45‐52 wk E: Hylan G‐F 20 SF‐36 pain 20 25.6 46.7 19.8 (I) 54.4% (I)
    C: Orthovisc   20 36.4 37.7    
Atamaz 2005 1‐4 wk E: Hylan G‐F 20 WOMAC function (Likert) 20 58.3 40.1 ‐11.9 (I) ‐28.7% (I)
    C: Orthovisc   20 41.5 35.2    
Atamaz 2005 5‐13 wk E: Hylan G‐F 20 WOMAC function (Likert) 20 58.3 41.7 ‐11.3 (I) ‐27.2% (I)
    C: Orthovisc   20 41.5 36.2    
Atamaz 2005 14‐26 wk E: Hylan G‐F 20 WOMAC function (Likert) 20 58.3 41.9 ‐16.7 (I) ‐40.2% (I)
    C: Orthovisc   20 41.5 41.8    
Atamaz 2005 36 wk E: Hylan G‐F 20 WOMAC function (Likert) 20 58.3 38.6 ‐17.8 (I) ‐42.9% (I)
    C: Orthovisc   20 41.5 39.6    
Atamaz 2005 45‐52 wk E: Hylan G‐F 20 WOMAC function (Likert) 20 58.3 38.9 ‐15.5 (I) ‐37.3% (I)
    C: Orthovisc   20 41.5 37.6    
Atamaz 2005 1‐4 wk E: Hylan G‐F 20 SF‐36 physical functioning 20 35.5 57.2 12.0 (I) 27.0 (I)
    C: Orthovisc   20 44.5 54.2    
Atamaz 2005 5‐13 wk E: Hylan G‐F 20 SF‐36 physical functioning 20 35.5 61.7 29.2 (I) 65.6% (I)
    C: Orthovisc   20 44.5 41.5    
Atamaz 2005 14‐26 wk E: Hylan G‐F 20 SF‐36 physical functioning 20 35.5 55.7 20.2 (I) 56.9% (I)
    C: Orthovisc   20 44.5 44.5    
Atamaz 2005 36 wk E: Hylan G‐F 20 SF‐36 physical functioning 20 35.5 45.0 4.8 (I) 10.8 (I)
    C: Orthovisc   20 44.5 49.2    
Atamaz 2005 45‐52 wk E: Hylan G‐F 20 SF‐36 physical functioning 20 35.5 54.0 32.0 (I) 71.9% (I)
    C: Orthovisc   20 44.5 31.0